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Abstract
There is currently a problem in that cancer patients engaging in hospice may experience an
excessive amount of perceived pain and a decreased quality of life. The purpose of this study
was to explore an intervention that could lessen the perceived pain experienced by, and increase
the quality of life of, cancer patients engaging in hospice. Immersion music virtual reality
(IMVR) allows a user to interact with a realistic, computer-generated environment. 3D music
(IMVR) is likely suited for pain management with patients in hospice and was used for this
study. The theory for the study is the gate control theory. The model for the study is the
biopsychosocial model. This study focused on whether there is a difference in pain experienced,
pain perceived, and quality of life for cancer patients in hospice using only morphine and
patients using IMVR and morphine. A two-group nonexperimental design addressed the research
problem using archival data from the National Hospice and Palliative Care Organization.
Participants included 176 (88 control group, 88 IMVR groups) adult cancer patients in hospice.
This study provided valuable knowledge for the use of IMVR and treatment of chronic pain,
which promises to facilitate positive social change in terms of improving the quality of life for
cancer patients in hospice.
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Chapter 1: Introduction to the Study
This quantitative research study was designed to address a gap in the literature
concerning the need for further information to improve pain management for cancer
patients who suffer chronic pain at the end of life. While there has been substantial
research supporting the use of virtual reality (VR) and immersion music virtual reality
(IMVR) in particular for chronic pain management, investigations have been conducted
to further understand VR’s role in chronic pain management with patients in hospice (Li,
Montano, Chen, & Gold, 2011).
In this study I investigated those patients’ perceived pain, experienced pain, and
quality of life, and assessed whether there were a difference in those three categories for
patients using only morphine and those using IMVR and morphine. This study has
promoted positive social change by potentially improving the quality of life for cancer
patients in hospice. In this chapter, I provide an in-depth description of the background
followed by the problem statement, the purpose, the research questions and hypotheses,
and the theoretical foundation of my study. The chapter has ended with a discussion of
the nature of the study, definitions, assumptions, scope and delimitations, limitations, the
significance of the study, and a summary.
Background
There was a gap in knowledge concerning the use of both morphine and IMVR
for decreasing chronic pain in cancer patients in hospice. Addressing the need for further
information to improve pain management for cancer patients, who suffer chronic pain,
may provide a model specifically compatible with medical constructs for good end-of-life
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care. I used the gate control theory (Melzack and Wall, 1965) to examine the role
psychological factors play in perception and experience of pain, and the biopsychosocial
models of pain (Engel, 1980) to address the biological pathophysiological components of
pain.
Gazerani (2016) stated that (VR) technology creates a sense of immersion in a
virtual environment analogous to the real world. VR has increasingly gained attention for
pain management based on current evidence demonstrating its analgesic affects in certain
experimental, acute and chronic pain conditions. Based on recent studies, VR-induced
distraction has been indicated highly effective in alleviating pain. The analysis found that
VR was more effective in experimental pain compared to clinical pain. Gazerani
reviewed another study and found strong overall evidence for immediate and short-term
pain reduction and a moderate evidence for the reduction of pain and functional
impairment after application of immersive VR. The study concluded that 3-D immersive
virtual environments have resulted in lower subjective pain ratings, promising analgesic
potentials of VR in acute pain conditions, and positive effects of VR for chronic pain
conditions. Gazerani stated that it is not yet known if VR could contribute to relief of
anxiety or other comorbidities accompanying chronic pain conditions. It is also not
known which type of chronic pain would respond better to VR and if there would be pain
elevation after VR. Gazerani concluded that it seems reasonable to consider VR as a
potentially valuable tool for chronic pain management. However, lack of sufficient
evidence and potential challenges logically call for more efforts to obtain a better
understanding of VR both in design and application for an optimal use in chronic pain
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management. Gazerani also concluded that future studies may consider investigating the
effects of age, gender, race and level of disability-functionality or medical status;
identifying different factors that can affect analgesic effect of VR including quality,
content, form and level of complexity; and underpinning VR mechanisms at
psychological and neurological levels.
According to Li et al., (2011), studies have investigated VR for chronic pain
management describing VR as a fast developing new technology, and finding that pain
was significantly lower for participants using VR. Currently, VR headsets or
multiprojected environments are used to generate realistic images, sounds and often
sensations that stimulate a user’s physical presence in a virtual environment. Cancer
hospice patients were able to interact with 3D worlds with the use of VR (Oyama, 1997).
VR may very well decrease the pain, unpleasantness, and anxiety associated with painful
cancer procedures and treatments.
Problem Statement
There was currently a problem with cancer patients engaging in hospice care
experiencing an excessive amount of perceived pain and a decreased quality of life. Past
research indicated there was a link to VR and morphine for pain management with
patients in hospice. In particular, an online journal (Li et al., 2011) noted intravenous
medication alone was used with patients in hospice. However, few studies have been
conducted to explore patients in hospice using VR. The current state of VR as a tool for
pain management was still in its early developmental stages. In addition few studies have
looked at the positive effects on patients in hospice care using VR and morphine.
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According to Smith et al. (2012) hospice care and other palliative care services at the end
of life have increased, and most patients are enrolled in hospice less than 3 weeks before
their deaths, which limits the benefit they may gain from these services. Understanding
the limitations of the past studies, this study explored the integration of morphine and
IMVR in relieving pain for patients in hospice and the length of time necessary for the
treatment to be effective. Examining these patients in a hospice setting conjunction with
length of time has possibly aided understanding of how the integration of morphine and
VR can maintain a successful end of life experience.
Recent research has indicated VR, when linked to morphine treatment, has been
effective for pain management (Li et al., 2011). These authors noted VR can decrease the
unpleasantness and anxiety associated with common painful cancer procedures and
treatments. Although these studies explored the power of VR and morphine to control
pain in cancer patients, there was very little research regarding the use of VR and
morphine with cancer patients in hospice.
VR as a tool for pain management is still in its early developmental stages (Li et
al., 2011). Li et al. (2011) found immersion music VR to be effective as a
nonpharmacological intervention for pain management with adult cancer patients in
hospice. IMVR allows a user to interact with a realistic, computer-generated
environment. An IMVR system typically consists of a 3-dimensional (3D) computer
generated environment that renders an interactive virtual experience. IMVR experiences
are primarily visual and auditory. In this study, I identified the effects IMVR and
morphine interventions have on cancer patients in hospice.
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According to National Hospice and Palliative Care Organization (NHPCO, 2013),
the total number of days that a hospice patient receives care is referred to as the length of
service. Length of service is influenced by a number of factors including disease course,
timing of referral, and access to care. The hospice team (e.g., physicians and nurses)
develops a care plan that meets each patient’s need for pain management (NHPCO,
2013). In this study, sampling was the process of selecting participants from the
population of interest. Every member of the population of interest had an equal
opportunity of being selected. In this study, the sampling frame listed all individuals who
were representative of the cancer hospice population. The sample for this study was
drawn from archival data provided by NHPCO. The research helped fill the gap by
focusing specifically the effectiveness of the integration of morphine and VR: on pain
management with adult cancer patients in hospice by decreasing pain intensity and
unpleasantness, while increasing comfort and support (Li et al., 2011).
Purpose of the Study
The purpose of the current study was to explore an intervention that could lessen
the perceived pain experienced by, and increase the quality of life of, cancer patients
engaging in hospice. This study was designed to determine if a link exists between
morphine and IMVR and hospice cancer patients’ experiences of pain, perceptions of
pain, and quality of end of life. This study’s dependent variables were (a) the experiences
of pain, perceptions of pain, and quality of life for end-of-life cancer patients; and (b) the
use of morphine and IMVR.
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Research Questions and Hypotheses
RQ1: Is there a difference in pain experienced by hospice cancer patients using
(a) only morphine or (b) IMVR and morphine?
H0l: There is no difference in pain experienced by hospice cancer patients using
(a) only morphine or (b) IMVR and morphine.
HA1: There is a difference in pain experienced by hospice cancer patients using
(a) only morphine or (b) IMVR and morphine.
RQ2: Is there a difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine?
H0l: There is no difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine.
HA2: There is a difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine.
RQ3: Is there a difference in perceived quality of life by hospice cancer patients
using (a) only morphine or (b) IMVR and morphine?
H0l: There is no difference in perceived quality of life by hospice cancer patients
using (a) only morphine or (b) IMVR and morphine.
HA3: There is a difference in the perceived quality of life by hospice cancer
patients using (a) only morphine or (b) IMVR and morphine.
Theoretical Foundation
I used one theory, the gate control theory (Melzak and Wall, 1965), and one
model, the biopsychosocial model (Engel, 1980) for the theoretical framework for this
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study. Melzack and Wall’s (1965) gate control theory holds that the human painmodulating system involves a neural gate present in the spinal cord. This gate can open
and close, thereby modulating a person’s perception of pain. The gate control theory
suggests that psychological factors play a role in perceptions of pain (Melzack, 1996).
This theory also suggests that the level of attention paid to the pain, the emotion
associated with the pain and the past experience of the pain all play a role in how the pain
will be interpreted (Melzack & Wall, 1965). The gate-like function proportions the
amount of conveyed impulses from the periphery. The periphery transmits nerve signals
to and from the central nervous system of the dorsal horn. Through inhibitory processes
at the neuronal level, the quantity and intensity of the signals of the central nervous
system are controlled (Gatchel, Peng, Peters, Fuchs, & Turk, 2007).
Engel’s (1980) biopsychosocial model focuses primarily on the construal of the
biological or pathophysiological component of pain (Gatchel et al., 2007). Theorist
Erikson (1986) used the term “psychosocial” to describe the interplay between our inner
emotional lives (psycho), and our outer social circumstances (social). Erikson theorized
the late adulthood stage of life as defined by a conflict between ego integrity and despair.
Adults at this stage feel content if they look back at their lives and feel that they have
been productive and happy. They try to find a sense of meaning in their lives that will
help them face the inevitability of death. Gatchel et al. (2007) emphasized the significant
role that psychosocial factors potentially play in the perception of pain. According to
Turk and Flor (1999), the biopsychosocial model views illness as an interaction between
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biological, psychological, and sociocultural variables that shape the persons response to
pain.
Nature of the Study
This quantitative study was designed to answer the question: “Is there a difference
in pain experienced, pain perceived, and quality of life for cancer patients in hospice
using only morphine and patients using IMVR and morphine?”
A report by the NHPCO (2013) outlined the demographic characteristics of the
two groups (experimental and control). The characteristics are as follows:
More than half of hospice patients were females. In 2012, 83.4% of hospice
patients were 65 years of age or older and more than one-third of all hospice
patients were 85 years of age or older. Following U. S. Census guidelines, the
NHPCO reported that Hispanic ethnicity is a separate concept from race. In 2012,
more than 6% of patients were identified as being of Hispanic or Latino origin.
Percentages of hospice patients by race were accounted for by Whites/Caucasians
(82.8%). Today, cancer diagnoses account for less than half of all hospice
admission (37.7%). (NHPCO, 2013; pp. 6-7)
Quantitative research involves a detailed method of data collection and analysis. I
conducted secondary analysis of archival data from intake/finish assessments (preexisting participants) for this study. “Archival data” refers to research information
collected for other purposes that can subsequently be used by others as comparison data
or as part of new research. I hypothesize that an analysis of this data would identify a
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relationship among variables (i.e., perception of pain, experience of pain, morphine
medication only, morphine medication and IMVR, and quality of life).
The independent variable (morphine only) was the variable that was changed or
controlled to test the effects on the dependent variable. The dependent variable (IMVR
and morphine) was tested and measured in the experiment. The dependent variable
responded to the independent variable. The null hypothesis was that there would be no
between-group differences in the dependent variables. The alternative hypothesis was
that there would be a between-group difference in the dependent variables (i.e., pain
perception and pain experience). In this study, the primarily interest was the quality of
life of the population of interest. However, I investigated if there would be in- betweengroup differences in pain perceived or experienced, and explored the possibility that the
between-group differences in quality of life are moderated by the participants’ pain
(perceived and/or experienced).
I utilized archival data for the population of adult cancer patients in hospice using
the NHPCO data. Cancer is the primary diagnosis for nearly 37% of hospice patients. The
NHPCO represents over 80% of hospices nationwide (http://www.nhpco.org).
Definitions
Throughout this study, I used specific terms to discuss different aspects of the
research. These terms are defined in this section to provide clear and concise
understanding:
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Chronic cancer pain: Chronic cancer pain is pain lasting beyond the normal
expectancy for an illness to be resolved. Pain that can be persistent and pain can be
stressful for body and soul (Portenoy & Hagen, (1990)).
End-of-life care: End-of-life care is a term used to describe the support and health
care given during the time surrounding death (Westerhoff, 2017).
Hospice: This term refers to an approach to end-of-life care, and to a facility for
supportive care of terminally ill patients (National Hospice Palliative Care, 2013).
Immersion music virtual reality: IMVR is a system that typically consists of a 3dimensional (3D) computer generated environment that renders an interactive virtual
experience (Chlan, 2013).
Nonpharmacological analgesics: Nonpharmaceutical analgesics are methods for
treating pain and suffering without using medications. Musical therapy is a nonpharmacologic method aimed at promoting relaxation, alteration in mood, a sense of
control and self-expression (Pak & Micalos, 2015).
Pain experienced: Pain experienced is a term that describes painful experience
such as aches, soreness, and physical discomfort (Sagha & Eshelman et al., 2018).
Pain management: Pain management is an approach for controlling or reducing
pain, easing suffering and improving the quality of life for patients living with pain. The
treatment approaches to chronic pain include nonpharmacological (such as VR) and
pharmacologic (Sagha, Eshelman et al., 2018).
Pain perception: Pain perception is a reaction to pain influenced by genetic,
psychological, social, and cultural variables (Sagha, Eshelman et al., 2018).
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Quality of life: This term refers to the general well-being of an individual. This
includes all social, emotional, and physical aspects of the individual’s life (Sagha,
Eshelman et al., 2018).
Virtual reality: VR is a technology that enables a user’s immersion in a virtual
world. VR has been used in clinical settings as a nonpharmacological form of pain
management that is thought to alter the body’s pain modulation system (Li et al., 2011).
Assumptions
I adopted several assumptions were going into this study. First, I assumed that
every cancer patient in hospice was given morphine for pain. This assumption was based
on findings from the literature review. Another assumption was the success of IMVR
combined with morphine can be determined by the generalizability to the population at
large. This assumption was based on the validity and reliability of assessment tools used
by NHPCO in their dataset. Finally, I assumed that each hospice patient’s identifying
characteristics would be matched effectively with data collected from the archives. This
assumption was based on using archival data and the particular demographic information
that was collected.
Scope and Delimitations
This study examined the effects morphine and IMVR have on cancer patients in
hospice. The control group design allowed me to utilize archival data that already existed
for cancer patients in hospice using the same measurement tools. According to the
NHPCO (2013), length of services refers to the total number of days that a hospice
patient receives care. Length of service can be influenced by a number of factors
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including disease course, timing of referral, and access to care. The criteria for
participation in the study required that the patient must: (a) have a primary diagnosis of
concern and currently be in hospice, (b) be able to speak English, (c) have no vision or
hearing impairment, (d) be female, (e) be at least 65 years of age, (f) be Caucasian and
(g) be receiving regularly scheduled medication.
The delimitations of my study explained the exclusion criteria for participation in
the study, excluding everyone not meeting the criteria. Those would be participants that
were outside the scope of my study. Another delimitation of my study was to narrow the
focus of my research questions. This limits my ability to answer questions beyond the
scope of my study.
Limitations
A possible limitation of this study was the population and sample size. Due to the
availability of archival data and the control group design, internal validity was limited
due to the selection process. Another possible limitation of this study was its reliance on
the data gathered from questionnaire-based measures. This study was limited because the
findings from the chosen sample were generalizable only to the general population of
hospice patients.
Significance of the Study
This research was unique because it addressed the need for further information to
improve pain management for cancer patients who suffer chronic pain at the end of life.
As indicated above, while there were substantial research supporting the use of VR for
chronic pain management, investigations are still being conducted to further understand
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VR’s role in chronic pain management with patients in hospice (Li, et. al, 2011). The
results of this study provided needed insight into the processes by which morphine and
IMVR together effectively decreased pain in these patients. Insights from this study may
aid health care teams in helping cancer patients in hospice cope successfully with pain,
thus enhancing the patient’s quality of life at the end of their life. This research provided
valuable knowledge regarding the use of IMVR in the treatment of chronic pain, which
promises to facilitate positive social change in terms of improving the quality of life for
cancer patients in hospice.
Summary
With many of the issues that cancer patients in hospice face when it comes to the
end-of-life care, it was important to understand the physical and emotional suffering that
affected them. In this study, the focus measured and defined the experiences and
perceptions of suffering, and asked, “How is pain perceived, experienced, expressed, and
responded to by the patient?” A significant difference in pain experienced, pain
perceived, and quality of life between hospice cancer patients using only morphine, and
those using morphine and IMVR in conjunction was identified.
The purpose of the current study was to explore an intervention that could lessen
the perceived pain experienced by, and increase the quality of life of, cancer patients
engaging in hospice. In this study I explored a possible way to alleviate the excessive
pain and increase quality of life. The results of this study addressed the need for further
information to improve pain management for cancer patients who suffer chronic pain at
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the end of life. The research method addressed the research questions and helped fill the
gaps in the literature as described by Li et al. (2011).
The next chapter includes a review of the theoretical and empirical literature
pertaining to pain management for adult hospice cancer patient.

Chapter 2: Literature Review
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Introduction
A thorough literature review identified that there has been little research on using
VR with cancer patients in hospice. The current problem was that cancer patients
engaging in hospice experience an excessive amount of perceived pain and a decreased
quality of life. The purpose of the current study was to explore an intervention that could
lessen the perceived pain experienced by, and increase the quality of life of, cancer
patients engaging in hospice. This chapter is an exploration of the literature relevant to
understanding pain management. This was done through a review of the empirical work
addressing the possible linkage between the emotional/physical experiences of end of life
cancer patients and pharmacological analgesics and IMVR.
Early research has shown many cancer patients nearing the end of life tend to
respond well to morphine (Kaye, 1990). Although oral opiate is clearly the effective
analgesic given orally, most patients will require an alternative to the oral opiate due to
factors such as: nausea, vomiting, sedation, delirium, bowel obstruction, swallowing
impairment, and how the body is affected by oral opioids after administration in terms of
its absorption, distribution, metabolism, and excretion (Barnett, 2001). Intravenous opiate
is another option. The challenge was to reliably determine intravenous equivalent
morphine dose compatible with the oral opioid dose.
Although Kaye (1990) and Mahrer (2009) explored pain in cancer patients, a
thorough review of recent literature identified that there has been little research using VR
with cancer patients in hospice for pain management. More recent research indicates that
VR is a relatively new technology that enables individuals to immerse themselves in a
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simulated world, thus distracting these patients and resulting in a nonpharmacologic
analgesic (Forest, 2017). Earlier studies have addressed the use of nonpharmacologic
analgesics and they are the focus of the review that follows. A VR tool for pain
management is still in its early development stages (Jones, Moore, & Choo, 2016).
Johnson and Coxon (2016) found IMVR to be effective as a nonpharmacologic
intervention for pain management with adult cancer patients. However, this technique has
not been used with cancer patients in hospice, which could be a group affected positively
by this technique.
The remainder of this chapter provides insights into the current study’s literature
review process, theoretical foundation, relevant literature, and the study’s key variables
and concepts. The chapter concludes with a summary.
Literature Search Strategy
I used electronic searches to gather relevant articles. The databases searched
included PubMed, Sage Online Journals, Science Direct, NCBI Articles, and Psych
INFO. The search terms used were pain management, virtual reality, morphine, cancer
pain, chronic pain, pain perception, quality of life, pain relief, treatment, satisfaction,
pain experienced, care at the end of life, and end-of-life. The articles selected were dated
from 1965 to 2018. Although most articles were are from recent years, some older ones
are included in order to provide a better understanding of the background of this study. A
limited number of database sources for music VR relating to chronic pain dates from
2013 to 2014. Most of the information on this review came from articles focused on pain
management, which was the basis for this research.
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Theoretical/Conceptual Foundation
I used one theory, the gate control theory (Melzak and Wall, 1965) and one
model; the biopsychosocial model (Engel, 1980) as the theoretical framework for this
study. Melzack and Wall (1965) gate control theory holds that the human painmodulating system involves a neural gate present in the spinal cord. This gate can open
and close thereby modulating a person’s perception of pain. The gate control theory
suggests that psychological factors play a role in perceptions of pain (Melzack, 1996).
This theory also suggests that the level of attention paid to the pain, the emotion
associated with the pain and the past experience of the pain all play a role in how the pain
will be interpreted (Melzack & Wall, 1965). The gate-like function proportions the
amount of conveyed impulses from the periphery. The periphery transmits nerve signals
to and from the central nervous system of the dorsal horn. Through inhibitory processes
at the neuronal level, the quantity and intensity of the signals of the central nervous
system are controlled (Gatchel et al., 2007).
Engel’s (1980) biopsychosocial model focuses primarily on the construal of the
biological or pathophysiological component of pain (Gatchel et al., 2007). Theorist
Erikson (1986) used the term “psychosocial” to describe the interplay between our inner
emotional lives (psycho), and our outer social circumstances (social). Erikson theorized
the late adulthood stage of life as defined by a conflict between ego integrity and despair.
Adults at this stage feel content if they look back at their lives and feel that they have
been productive and happy. They try to find a sense of meaning in their lives that will
help them face the inevitability of death. Gatchel et al. (2007) emphasized the significant
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role that psychosocial factors potentially play in the perception of pain. According to
Turk and Flor (1999), the biopsychosocial model views illness as an interaction between
biological, psychological, and sociocultural variables that shape the persons response to
pain. The questions addressed in this study can be linked to Melzack and Wall’s (1965)
gate control theory and the biopsychosocial model (Engel, 1980).
Gate Control Theory
The gate control theory suggests that psychological factors play a role in pain
perception (Melzack, 1996). Melzack and Wall (1965) suggested that the level of
attention paid to the pain, the emotion associated with pain and the past experience of the
pain, all play a role in how the pain will be interpreted. According to this theory, the
spinal cord contains a neurological “gate” that either blocks pain signals or allows them
to continue on to the brain. This “gate” operates by differentiating between the types of
fibers carrying pain signals. Pain signals traveling via small nerve fibers are allowed to
pass through while signals sent by large nerve fibers are blocked. The gate control theory
is often used to explain chronic pain. Following an injury, pain signals are transmitted to
the spinal cord and then up to the brain. Melzack and Wall suggested that before the
information is transmitted to the brain, the pain messages encounter “nerve gates” that
control whether these signals are allowed to pass through to the brain. This gating
mechanism takes place in the dorsal horn of the body’s spinal cord. Both large and small
fibers for touch, pressure, and other skin senses carry information to two areas of the
dorsal horn. The two areas either transmit cells that carry information up to the spinal
cord to the brain or the inhibitory interneurons that halt or impede the transmission of
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sensory information. The authors suggested that an increase in normal touch sensory
helps to inhibit the pain fiber activity, therefore reducing the perception of pain. Melzack
and Wall proposed that a mechanism in the dorsal horns of the spinal cord acts like a gate
that inhibits or facilitates transmission from the body to the brain on the basis of the
diameters of the active peripheral fibers, as well as the dynamic action of brain processes.
As a result psychological variables such as past experiences, attention, and other
cognitive activities have been integrated into current research and therapy on pain
processes.
The gate control theory presents a physiological explanation for previously
observed effect of psychology on pain perception. Concepts derived from the specificity
theory and the peripheral pattern theory (Moayedi & Davis, 2012); give way to the gate
control theory. The gate control theory is considered to be one of the most influential
theories of pain because it provided a neural basis which reconciled the specificity and
pattern theories and ultimately revolutionized pain research. The gate control theory
remains the only theory of pain that most accurately accounts for the physical and
psychological aspects of pain perception.
Implications of gate control theory for the present study. The gate control
theory of pain is still considered the dominant theory today. The gate control theory
accounts for the clinically recognized importance of the mind and brain in pain
perception. This theory provides a physiological basis for the complex phenomenon of
pain. It does this by determining the complex structures of the nervous system. The basic
conception remains unchanged. Melzack and Wall (1965) visualized the mechanism of
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pain perception in a new dimension and it has laid the foundation for various pain
management strategies. It inspired basic research and clinical applications. Melzack’s
work has led to advancements in the assessments of pain using the McGill Pain
Questionnaire. Assessment of patients experiencing pain is the cornerstone to optimal
pain management. The gate theory opened a psychological approach to be used for pain
management. This theory led to nonmedication treatment for pain. The pain management
strategy and its applications will be able to test the concepts of the gate-control theory of
pain in humans (Nathan & Rudge 1974).
Learning how the body responds to pain can help people understand
recommended treatments and develop strategies to minimize chronic pain (Deardorff,
2017). This author stated that the key element of the theory is the concept of a gate that
allows pain signals to reach the brain when it is open, and blocks the signals when it is
closed. This author noted that closing the gate resulted in less pain. Once the pain signal
is allowed through the spinal gate the brain can amplify it, decrease it, or ignore it
altogether. Various cognitive (thoughts) and emotional (depression, anxiety, etc.) factors
will determine what happen to the pain signal. Deardorff (2017) emphasized how the gate
control theory has influenced our perception of pain and explained why certain pain
treatments are effective. Concepts outlined in the gate control theory are often used to
explain and develop pain relief treatments, such as: electrical, spinal cord, and peripheral
nerve field stimulation. Deardorff explains how music therapy and auditory interventions
tap the power of distraction, allowing the brain to send a signal down the spinal cord to
close the pain gate while also minimizing the pain signal arriving to the brain itself.
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Deardorff concluded stating that an awareness of ways to moderate pain by opening or
closing pain gates can be applied to daily life. Sensory, cognitive, and emotional factors
that can close spinal nerves gates can all be used for chronic pain management. A mix of
sensory, cognitive and emotional chronic pain management strategies should be part of
everyday life for anyone who suffers from chronic pain.
Biopsychosocial Model
The biopsychosocial model (Engel, 1980) was proposed by Gatchel et al. (2007)
and focused primarily on the construal of the biological or the pathophysiological
component of pain. Dating back to the 17th century, disease and illness were described
pristinely as mechanistic biological processes. It was conceived that the experience of
pain was conveyed directly to the brain from the skin, without a psychosocial interplay
(Gatchel et al., 2007). Gatchel et al. (2007) emphasized the significant role that
psychosocial factors potentially play in the perception of pain. The biopsychosocial
paradigm is technical term for the concept of the “mind-body” connection. This is a
general model or approach stating that biological, psychological (thoughts, emotions, and
behaviors) and social (cultural, socio-economical, socio environmental) factors all play a
significant role in human function in the context of illness. The concept of the “mindbody” connection is used in psychology and clinical psychology.
The clinical application of the Biopsychosocial Model (Engel, 1980) focuses on
how physicians approach patients and the problems they present is influenced by the
conceptual models around which their knowledge is organized. The author focused on a
medical rather than a psychiatric patient to emphasize the unity of medicine and to help
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define the place of psychiatrists in the education of physicians of the future. The author
states that the biopsychosocial model is a scientific model constructed to take into
account the missing dimensions of the biomedical model. To the extent that it succeeds it
also serves to define the educational tasks of medicine and particularly the task and roles
of psychiatrists in the education of physicians of the future. The author examines how the
physicians approach clinical problems from the perspective of the systems-oriented
biopsychosocial model. In consideration of the model, the physician’s first source of
information is the patient himself. The clinical study begins at the person level and takes
place with a two-person system, the doctor-patient relationship. The data consist of
reported inner experience (feelings, sensations, thoughts, opinion, and memories) and
reported behavior. The clinical approach considers all information in terms of the system
to find a diagnosis for a single disease. The author then reconstructs in systems terms the
sequence of events comprising the acute phase of the illness. The patient experiences
something toward or exhibits some behavior or appearance that is interpreted as
indicating illness. The central nervous system is the integration and regulation of the
patient’s inner experiences and behavior and the physiological adjustments occurring in
response to the processes originating from the illness. The biopsychosocial model
provides a conceptual framework and a way of thinking that enables the physicians to act
rationally in areas now excluded from a rational approach. It motivates the physician to
become more informed and skillful in the psychosocial areas, and the model serves to
counteract the wasteful reductionist pursuit of what often prove to be trivial rather than
crucial determinants of illness.
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Currently, Novy and Aigner (2014) emphasized the biopsychosocial model in
cancer pain as a helpful way to comprehensively approach the conceptualizing and
treatment of pain in cancer patients at all stages of the disease process. Recent reviews
contain articles dated from 2012-2014, which advance the authors understanding of
biopsychosocial factors related to the cancer pain experience and the psychosocial
treatment for cancer pain. Recent publications have advanced the authors understanding
of psychosocial interventions for cancer pain and symptom management. In the last few
years, several reviews have emerged, which have found modest effect sizes for
psychosocial intervention in cancer management. The authors stated that an established
base of research on the importance of biopsychosocial model in cancer pain. The ability
to treat patients with cancer pain effectively will improve as a better understanding of
which treatment works for which patients.
Literature Review Related to Key Variables and/or Concepts
The current literature describes studies related to the construct of interest and
chosen methodology and methods that are consistent with the scope of the study. The
current literature describes ways researchers have approached the problems and the
strength and weakness inherent in their approaches. Mohamad, Eslam, Ahmad, and
Muayyad, (2018) assessed the effectiveness of VR distraction technology in reducing
pain and anxiety among female patients with cancer. The authors randomized a
controlled trial design used with a sample of 80 female patients with cancer at a
specialized cancer center in Jordan. Participants were randomly assigned into
intervention and comparison groups. The results of their findings showed that one session
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of the immersive VR plus morphine made a significant reduction in pain and anxiety
from self-reported scores, compared with morphine alone in cancer patients. The authors
concluded that immersive VR is an effective distraction intervention for managing pain
and anxiety among cancer patients using immersive VR as an intervention is more
effective than morphine alone in relieving pain and anxiety. The authors concluded that
using immersive VR as an intervention is more effective than using morphine alone in
relieving pain and anxiety in cancer patients and that VR is a safer intervention than
pharmacological treatment (Mohamad et al., 2018).
Cancer Pain Management
Greco, Roberto, Corli, and Deandrea (2014) updated a systematic review
published in 2008, which showed that according to the pain management index (PMI),
43.4% of patients with cancer were under treated. The authors discuss adequately in
treating cancer pain need to be identified, assessed, classified, and managed as part of a
multidimensional approach. Pain assessment and classification implies awareness of the
existence and importance of the problem and acknowledgement of its intrinsic subjective
nature (pain). Pain is always affected by cultural, emotional, spiritual, and behavioral
factors related to the host or to the macro and microenvironments. Valid and reliable
tools are also essential assessing pain using a numeric rating scale is preferred. The
authors state that new and more effective therapies are evidence-based guidelines that
have become available in recent years providing both the framework and tools to treat
cancer pain properly. But more accurate and better quality treatments cannot be
automatically expected. Reliable estimates based on evidence are needed from systematic
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reviews and meta-analysis. The review included observational and experimental studies
reporting negative PMI scores for adults with cancer and pain published from 2007 to
2013 and retrieved through MEDLINE, and Google Scholar. A systematic review
covering 26 studies from 1994 up to 2007 that adopted the Pain Management Index
(PMI) to assess the adequacy of pharmacologic pain therapy reported the rate of
potentially undertreated patient cases from 8% to 82%, with a weighted mean of 43%.
More recent studies seem to suggest lower levels of inappropriate analgesic care.
Therefore, the authors expected that in the last few years, the quality of cancer pain
management has improved. However, because differences in study design and setting do
not permit any solid conclusion, a formal evidence synthesis process is recommended to
investigate any possible time trend. The authors updated the previously systematic review
to assess whether any change could be detected in the quality of pain management in
adults with cancer, in terms of adequacy of analgesic prescription. In this article, the
authors describe the studies published after 2007, comparing the under treatment
estimates before and after 2007. The authors assessed the temporal trends from 1944 to
2013 in the whole sample of studies, and identified variables associated with under
treatment using a set of potential determinants. The MEDLINE search from November
2007 to September 2013 produced 2806 citations, and five additional cases were
identified through Google Scholar or from experts in the field. After removing duplicates,
2697 records remained. Of these, 2670 were discarded, because after reviewing the
abstracts they did not meet the inclusion criteria. The full text of the remaining 27 was
examined, and seven articles were excluded as not regarding cancer pain. The 20 studies
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that met the inclusion criteria were included in the current analysis of under treatment of
cancer pain.
Applications of morphine for chronic pain management in cancer patients.
Morphine is considered the standard opiate and the drug of first choice in the treatment of
moderate to severe cancer pain. The Pharmaceutical Journal (2013) states that morphine
remains a popular opioid analgesic for cancer-related pain. Numerous reports have
documented morphine as an effective analgesic for cancer patients. The published
research covered in this review will pertain to specific applications in which morphine
was used to alleviate pain in cancer patients.
One of the earliest studies involving morphine use during cancer care is oral
morphine for chronic cancer patients (Walsh, 1984). The study provides a brief
discussion of opiates during the last decade in controlling advanced cancer. The author
indicated that the use of morphine at St. Christopher’s Hospice since 1977, was the oral
opiate for more than 1700 patients for several chronic pains. The continuing care of
terminal cancer patients in 1979 clinical assessment confirms that 85-90% of patients
with advance cancer tolerated oral morphine and up to 95% get excellent pain control
(Mount, 1979 as cited by Walsh, 1984).
Schmitz (1985) describes morphine was first discovered in 1804 Paderborn,
Germany by Friedrich Serturner. Morphine is one of the oldest drug in existence for
relieving severe pain and suffering in patients. Morphine acts directly on the central
nervous system (CNS) to decrease the feeling of pain. It can be taken for both acute pain
and chronic pain (The American Society of Health-System Pharmacists, 2015).

27
Wiffen, Wee, and Moore (2016) determined the efficacy of oral morphine in
relieving cancer pain, and assessed the incidence and severity of adverse events. The
authors stated that this is the third updated version of a Cochrane review first published in
issue 4, 2003 of The Cochrane Library and the first update in 2007. Morphine has been
used for many years to relieve pain. Oral morphine in either immediate release or
modified release form remains the analgesic of choice for moderate or severe cancer pain.
The main results, seven new studies were identified in this update. The authors excluded
six, and one study is ongoing so also not included in this update. This review contains a
total of 62 included studies, with 4241 participants. Thirty-two studies used cross-over
design ranging from one to 15 days, with the greatest number (1) foe seven days for each
arm of the trial. Overall, the authors judged the included studies to be at high risk of bias
because the methods of randomization and dislocation concealment were poorly. The
primary outcomes for this review were participant reported pain and pain relief. The
authors concluded that morphine is an effective analgesic for cancer pain. Pain relief did
not differ between Mm/r and MIR. The author’s conclusions have not changed for this
update. The effectiveness of oral morphine has stood the test of time. The new studies
added to the review for the previous update reinforced the view that it is possible to use
modified release morphine to titrate to analgesic effect.
Winiarczyk and Knetki-Wroblewska (2016) addresses break through pain as a
brief episode of severe pain occurring in patients undergoing analgesic procedures in the
course of cancer. It affects about 70% of patients and significantly influences their quality
of life. It is important to identify specific types of pain and inducing factors. Treatment is
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based on modification of pain management including use of immediate release drug
formulations. The authors state that pain treatment is an integral part of management in
patients with cancer. Despite active treatment, in some patients pain control remains
unsatisfactory, which also applies to breakthrough pain. A lack of unambiguous
definition as well as a validated tool for assessment of pain still significantly implies the
diagnostics and treatment of break through pain. Management is based on modification of
the treatment of baseline pain, considering opioid drugs of immediate release, used in 1/6
of baseline drugs daily dose. Transmuscosal opioids ensure faster analgesic effect then
other oral formulations, and intranasal aerosol seems to be currently the most beneficial
route of administration.
Applications of morphine for chronic pain management in hospice patients.
Zeppelella, Davies, Eijgelshoven, and Jansen (2013) investigated the use of
opioid analgesics for the management of breakthrough cancer pain (BTCP). In this study,
a systematic literature search (2007-2010) resulted in ARBTCP morphine sulfate
immediate release, were synthesized using a network meta-analyses. The authors identify
many medications available for the management of breakthrough cancer pain (BTCP).
Physicians may require additional guidance in selecting an appropriate medication to suit
an individual patient’s needs. The authors identify all the evidence and assess the relative
clinical value of currently approach BTCP medications. The authors literature search
(2007-2010) resulted in 10 randomized controlled trails investigating the effects of BTCP
medications (intranasal fentanyl spray [INFS], fentanyl pectin nasal spray, fentanyl
sublingual tablets, fentanyl buccal soluble film, fentanyl buccal tablets, oral transmucosal
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fentanyl citrate, and morphine sulfate immediate release) were synthesized using a
network meta-analysis. The main outcome was pain intensity difference (PID) relative to
placebo up to 60 minutes often the intake of medication. The results were that INFS,
fentanyl pectin nasal spray, fentanyl buccal tablet, and oral transmucosal fentanyl citrate
showed greater PIDs relative to placebo than other BTCP medications 15 minutes after
intake. All other medications showed greater PIDs relative to placebo at 30 minutes,
except morphine sulfate immediate release, which did not show efficacy over placebo
until 45 minutes. Only INFS produced clinically meaningful pain relief at 15 minutes.
The conclusion from evidence was that all BTCP medications provided pain relief within
the time frame assessed.
Groninger and Vijayan (2014) describe options to improve analgesia and quality
of life for patients experiencing deliberating pain at the end of life. Pain assessment using
a validated tool helps tailor treatment plans and The World Health Organization (WHO)
pain ladder offers a guideline for approaching pain management. However, for the many
patients that are terminally ill, strong opioids are necessary for efficient and effective
analgesia. The authors explained that many persons experience significant pain in the
final months of life. Despite advances in understanding pain physiology and available
pharmacotherapies, many patients with terminal illness; such as cancer, report untreated
and undertreated pain. The authors also describe the pain assessment procedure.
Assessment of pain should include the patient’s pain intensities and the physical signs of
pain. Pain intensity can provide essential information about the effectiveness of current
interventions. Pain should be assessed regularly using a pain scale. There are several pain
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scales; such as, A Likert-type scale (rating pain from 0 to 10), the Wong-Baker FACES
Pain Rating Scale, and a visual Analog Scale. The author explained that clinicians should
begin with non-opioid analgesics should be used first and gradually progress to a more
potent analgesic until pain is relieved. For patients with terminal illness, opioid therapies
provide greatest analgesic relief. However, concerns about addiction and respiratory
depression inappropriately limit use of opioids in these patients. Another option is the use
of alternative opioid formulations and routes of administration to enhance pain
management. Patients may benefit from concentrated opioid elixirs, morphine, hydromorphine, oxycodone and methadone.
Prommer and Ficek (2012) provide an overview of the analgesic considerations
for elderly patients at the end of life. The authors state that pain is one of the symptoms
most frequently encountered in elderly patients at the end of life. The management of
pain in the elderly in general has been associated with under treatment. In the geriatric
population, the assessment of pain requires measurement of pain intensity, opioid
responsiveness, and impact of pain on patient’s psychological, social, spiritual, and
existential domains. The authors noted that effective pain management is guided by the
WHO analgesic stepladder, which categorizes pain intensity according to severity and
recommends analgesic agents based on their strength and works effectively in the elderly
patient population.
Berger (2013) addresses misconceptions about opioid use for pain management at
the end of life. By addressing pain early in patients who are seriously ill such as patients
with cancer could improve their quality of life. The author addresses four common
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misconceptions about opioids use for pain management at the end of life: (1) that dying
patients’ unconsciousness is necessarily unnatural and problematic; (2) that it is
necessary wrong to help with pain at the cost of some consciousness or length of life; (3)
that there are legal restrictions on doing so, and (4) that managing a patients pain
necessarily entails making a tradeoff about consciousness or length of life. The author
addresses the first misconception by stating that death is imminent for patients with
terminal illness and after administering morphine for two weeks, the patients slowly loses
consciousness; should the doctors turn off the morphine infusion to test rather the
morphine was the cause of the change in mental status? Absolutely not (Federation of
State Medical Boards of the United States [FSMB], 2004). Discontinuing an ongoing
opioid infusion in a terminal patient who slowly loses consciousness can intensify the
patient’s already moderate to severe pain. The author addresses another misconception
about pain relief at the end of life. This misconception is that it is not necessarily wrong
to help with pain at the cost of some consciousness or length of life. The author
implemented the four principles of ethical medical care to contend with three sets of
conflicting goals: Benefiting the patient and minimizing the burden of doing so, striving
to preserve life and providing comfort in dying, and meeting individual needs and those
of society. In cases such as this, the first two set of goals deals with the principle of
double effect, initially developed in the Catholic tradition from the thirteenth century
teaching of Thomas Aquinas. The principle states that an action that has two effects, one
good and one bad, is permissible if five conditions are met: (1) the act of giving morphine
to relieve pain is good, (2) only good effect (relieving pain) and not the bad effect
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(ending the patient’s life is intended), (3) the good effect is not achieved through the bad
effect (pain relief does not depend on hastening death), (4) there is no alternative way to
obtain the good effect (pain relief); if there were, that would be the appropriate cause of
action, (5) running the risk such as pain so intense that it could cause severe
consequences. The author stated that the main point of the principle is that the intention
of the caregiver is what matters, that is, it gives primacy to doing well in spite of the risk
of causing harm. It is not morally wrong to alleviate the patient’s pain, using whatever
dosages of opioids are necessary, at the cost of some consciousness or length of life. The
author addresses the legal restrictions of this kind of pain management. Physicians may
legally alleviate pain by prescribing control substances when there is legitimate medical
need. Physicians should not be reluctant to prescribed controlled substances used for
medical purposes, even those with high potential for abuse and dependence. The Federal
Controlled Substance Act (CSA) too, does not regulate medical treatment decisions such
as the selection or quantity of prescribed drugs. The author states the last misconception
addresses the belief that given patients such doses of opioids will necessarily reduce
consciousness or shorten of life. In a retrospective study of 238, Thorn and Sykes found
that there was no difference in survival between patients requiring escalating doses of
opioids and patients on stable doses. The author concluded that it behooves all physicians
who are privileged to care for patients at the terminal stages of life to be aware of the
doctrine of double effect as well as its legal and social ramifications and to know data
that clearly show that palliative sedation applied appropriately has no life shortening
effect.
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Origin of Virtual Reality
Yaakov (1987) describes that the earliest use cited by the Oxford English
Dictionary is in a 1987 article titled, “virtual reality”. Krueger (1983) describes “artificial
reality” as interactive immersive environments (or virtual realities), based on video
recognition techniques, that put a user in full, unencumbered contact with the digital
world; however, the origin of the term “virtual reality” can be traced back to 1938 to
Antonin Artaud. It is believed that the first try at VR came in the 1860, as artists began to
create three-dimensional virtual environments. VR can be traced back to 1957 when
Morton Helig invents a stimulator with 3D images along with smells, wind and sound to
create the illusion of reality. Today, VR has huge implications in the field of psychology
and psychological research. VR is becoming a powerful new tool for training
practitioners and treating patients.
Foreman and Korallo (2014) stated that VR (virtual environment technology) has
been widely available for 20 years. In that time, the benefits of using virtual environment
have become clear in many areas of application, including assessment and training,
education, rehabilitation and psychological research in spatial cognition. Pourmand,
Davis, Marchant, Whiteside, and Sikka (2018) evaluated the use of VR therapies as a
clinical tool for the management of acute and chronic pain. The authors state that recent
articles support the hypothesis that VR therapies can effectively distract patients who
suffer from chronic pain and from acute pain stimulated in trials. Clinical studies yield
promising results in the application of VR therapies to a variety of acute and chronic pain
conditions. The authors summarize their findings stating that current management
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techniques for acute and chronic pain, such as opioids and physical therapy, are often
incomplete or ineffective. VR trials demonstrate a potential to redefine the approach to
treat an acute and chronic pain in the clinical setting. The authors state that patient
immersion in interactive VR provides distraction from painful stimuli and can decrease
an individual’s perception of the pain. In this review, the authors discuss the use of VR to
provide patient distractions from acute pain induced from electrical, thermal, and
pressure conditions. The authors also discuss the application of VR technology to treat
varies chronic conditions in both outpatient and inpatient settings.
Application of VR for chronic pain management.
While there is substantial research supporting the use of VR for chronic pain
management, investigations must be conducted to further understand VR’s role in chronic
pain management with patients in hospice (Li et al. 2011). Lasich (2012), describes VR
as a powerful pain management tool. The author explains that researchers have dedicated
years to developing and studying this new method of pain management. VR treatment
actually changes the way the brain can perceive pain by flooding it with less threatening
stimuli. By using VR, the researchers can actually see a reduction in pain perceptions as
the distracted brain focuses less on painful stimulation. The author explains that today’s
virtual world is getting very sophisticated. Using a combination of a clear flat screen TV
and some noise-cancelling headphones to block out any distractions, VR can be created
in someone’s living room. The right VR can distract the brain causing pain relief while
experiencing in this virtual world. The author takes pain management strategy one step
further. If one were to focus his or her attention anywhere else besides the pain, she or he
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could experience some pain relief. VR is a means of redirecting focus; people in pain
have a hard time maintaining focus. Without being absolutely submerged in an artificial
world, the brain slowly drifts back to the presence of pain. The author notes that after
using VR over and over, a VR user then is able to reproduce the experience by
visualizing it in a quiet room. VR distraction has been proven to be very useful in
controlling pain.
A review by Gupta, Scott, and Dukewich (2018) focused on studies that gave
evidence to the distraction or non-distraction mechanisms by which VR leads to the
treatment of pain. The authors reviewed articles from 2000 to July 29, 2016, focusing on
studies considering mechanisms by which VR can augment pain relief. The data was
collected through a search of MEDLINE and Web of Science using the key words of
“virtual reality” and “pain” or “distraction”. The authors identified six studies: four small
randomized controlled studies and two prospective/pilot studies. The search results
provided evidence that distraction is a technique by which VR can have benefits in the
treatment of pain. Both adult and child populations were included in these studies. In
addition to acute pain, several studies looked at chronic pain states such as headaches and
fibromyalgia. These studies also combine VR with other treatment modalities such as
biofeedback mechanisms and cognitive behavioral therapy. The authors concluded that
these results demonstrated that in addition to distraction, there are novel mechanisms for
VR treatment in pain, such as producing neurophysiologic changes related to
conditioning and exposure therapies. If these new mechanisms can lead to new treatment
options for patients with chronic pain, VR may have the ability to help reduce opioid use
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and misuse among chronic pain patients. The authors concluded that more studies are
needed to reproduce results from prospective/pilot studies in large randomized control
studies.
Li et al. (2011) explored clinical and experimental applications of VR for acute
and chronic pain management, focusing specifically on current trends and recent
developments. The authors state that VR has been used to manage pain and distress
associated with a wide variety of known painful medical procedures. In clinical settings
and experimental studies, participants immersed in VR experience reduced levels of pain,
general distress/unpleasantness. Participants reported a desire to use VR again during
painful medical procedures. Investigators hypothesize that VR acts as a
nonpharmacological form of analgesia by exerting an array of emotional affective,
emotion-based cognitive and attentional processes and the body’s intricate pain
modulation system. The authors stated that while the exact neurobiological mechanisms
behind VRs action remain unclear, investigations are currently underway to examine the
complex interplay of cortical activity associated with immersive VR. Recently, new
applications, including VR, have been developed to augment evidence-based
interventions, such as hypnosis and biofeedback, for treatment of chronic pain. The
authors proposed mechanistic theories highlighting VR distraction and neurobiological
explanations and concluded that with a new direction in VR research, implications and
clinical significance.
Keogh (2016) reviews research that supports VR and pain management. This
research has shown that psychology is important in how we experience pain and how
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painful sensations can be manipulated by what we think and feel. Approaches to pain
relief are promising because of advanced technology. VR games are successful in
tackling acute pain by focusing on other things. The author reviews a new study that
sheds light on how VR might work and how it could be improved in the future. This
study shows how an advance in computer graphics in the gaming world has become more
excessive. An example would be immersive VR systems are starting to be developed for
use by patients during painful procedures; such as, dental procedures or changing burns
dressings. It was explained that by placing oneself in the immersive virtual world, one
self can be distracted from the painful experience. While only a few randomized
controlled trails have tested the efficacy of such distraction there is some evidence that it
might work. The author expresses how VR lowers the amount of pain we experience
using visual images, the sounds or simply the activity of pressing buttons. A review of
the new study as published by the Royal Society, examines the effects of visual and
auditory sensory information on pain. The new study let a group of 27 healthy volunteers
immerse their hands in ice water (around 1 degrees), to the point where they could not
tolerate it, while simultaneously playing a VR game. The first person racing game, set in
a futuristic world, was presented to them through a head mounted display and noise
cancelling headphones. The new study examined to see whether pain tolerance levels
were affected by different amounts of sensory input from the game. These included none
at all, only the music from the game, only the visual images from the game, and both
music and images together. The study found that the highest pain tolerance levels
occurred when visual and auditory sensory inputs were combined. Playing music by itself
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or just showing images, boosted pain-tolerance levels. The study argued that sound may
enhance the effects of the distraction from the game. The study suggested that to get more
efficient pain relief, it may be worth exploring whether different types of sound are
important and it may also be possible to add other multi-sensory interactions such as
smell and touch to the gaming experience. The conclusion is that it demonstrates an
innovative way in which we could potentially use VR to manipulate different sensory
inputs, both on their own, and together to best target and understand pain. The study
expresses that if such effects do translate into the clinic, there may be lessons for pain
management beyond just playing VR games. The study states that there is a need for clear
evidence that pain management can work in practice, and doesn’t make things worse. But
from a research point of view, it is all very exciting. Not only does it seem like we are
getting better at tackling pain using techniques such as VR, the technique themselves are
actually helping us better understand the multisensory experience of pain.
Brinie, Hons, Noel, and McGrath (2013), found a systematic review of clinical
trials that use distraction can help reduce pain. That is because the psychological effect of
anticipating pain can actually make the pain worse. The author expresses that beyond
studies of distraction; we are also starting to see other examples of how VR could be use,
and even incorporated into cognitive behavioral approaches to chronic pain management.
Weina, Choo, Gromala, Shaw, and Squire (2016), stated that although VR
applications have been shown to reduce many forms of acute pain, such research of VR
applications and there effects on chronic pain is still at its infancy. In this study, the
authors designed a VR game Cryoslide, and examined its analgesic effect on chronic pain
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patients, its end users, in a clinical setting. In this randomized, controlled crossover
clinical study of 20 chronic pain patients, Cryoslide significantly reduced perceived pain
compared to the base line and the control group. The results demonstrated that Cryoslide
can be effectively used as an analgesic intervention for chronic pain management to
lessen pain intensity during short term symptoms spikes. The findings indicated that
during the VR sessions, Cryoslide could significantly reduce the perception of pain
intensity for chronic pain suffers. The survey consisted of 4 males (20%) and 16 females
(80%), ages from 30 to 75 years old. Pain intensity during and after the intervention, was
measured. For pain intensity after the intervention, the two groups of the VR intervention
and self-meditated control where not significantly different using repeated measures was
ANOVA (F (2,38) – 1,377, P – 0265). However for pain intensity during the intervention,
there was a significant difference between the VR intervention and control groups (F
(2.38) -21.473, P< 0.001, R – 0.505). Compared to the baseline, there was a 36.7%
reduction in pair intensity during the VR intervention using Bonferrini past hoc tests
(95% confidence interval (CT), .31443 to 11657; P < .001) compared to control group,
the VR intervention group also had a significant reduction in pain intensity (95%
confidence interval [CT], .27,397 to control group in pain intensity (P – 0.336).
Application of VR for pain management in cancer patients. The use of IMVR
may very well decrease the pain, unpleasantness and anxiety associated with painful
cancer procedures and treatments. A number of studies provide lines of evidence
supporting this argument.
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Triberta, Repetto, and Riva (2014) investigated the psychological factors
influencing the effectiveness of VR. In this study, the experience of pain is affected by
psychological factors. This review outlined the fundamental psychological factors
involved in the use of VR to provide pain management. The virtual environment has been
used as an efficient distraction tool in pain management; however, no systematic
approaches have explored the psychological factors that influence the effectiveness of
VR as a distraction technology. Eleven studies results suggested the importance of
different psychological factors in the effectiveness of the analgesic distraction. While
sense of presence influence the effectiveness of VR as a distraction tool anxiety as well
as positive emotions directly affects the experience of pain. The conclusion from this
study lead to future challenges for pain management by way of VR: adopting properly,
validated measures to access psychological factors and using different experimental
differences to better understand their complex effects. The authors stated that the study of
psychological factors in VR-based analgesic is in its infancy and, to date, it has not been
performed with validated and solid instruments. Analyzing the psychological factors one
by one, we provide some guidelines to develop and improve the study of VR-based
analgesia in the future.
Tashjian, Mosadeghi, and Spiegel (2017) compared 3D VR intervention to a 2D
distraction video for pain in hospitalized patients. Improvements in software and design
have made VR a practical tool for immersive-three-dimensional (3D), multisensory
experiences that distract patients from painful stimuli. The authors conducted a
comparative cohort study in a large, urban hospital with inpatients with an average pain
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score of 3/10 from any cause. Patients in the intervention cohort viewed a 3D VR
experience designed to reduce pain using the Samsung gears oculus VR headset: control
patients viewed a high definition, 2D nature video on a 14-inch beside screen. Pre-and
past intervention pain scores were recorded. Difference-in-difference scares and the
proportion achieving a half standard deviation pain response were compared between
groups. The authors’ result of the comparison was that the mean pain reduction in VR
cohort was greater than in controls (-1.3 vs -0.6 points, respectively; p = .008). A total of
35 (65%) patients in the VR Cohort achieved a pain response versus 40% of controls (p =
.01; number needed to treat = 4). No adverse events were reported from VR. The author
concludes that the use of VR in hospitalized patients significantly reduces pain versus
control distraction conciliation. These results indicate that VR is an effective and safe
adjunctive therapy for pain management in the acute inpatient setting; future randomized
trails should confirm benefits with different visualization and exposure periods. The
author state that although VR has been studied in a variety of conditions including wound
care, rehabilitation, and anxiety, its effectiveness for managing pain in hospitalized
patients has not been fully examined. In this study the authors found that the use of VR
intervention in a diverse group of hospitalized patients resulted in statistically significant
and clinically relevant improvements in pain versus a control distraction video without
triggering adverse events or altering vital signs. These results indicate that VR may be an
effective adjunctive therapy to complement traditional pain management protocols in
hospitalized patients. These authors also state that previous VR research has traditionally
focused on specific types of pain, our study is unique for evaluating VR across a wide
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range of somatic and visceral pain conditions. Because this study is focused on single
pain distraction visualization, future research should evaluate whether and how to tailor
VR content for specific pain syndromes, as this may have incremental benefits over a
single generic VR intervention. Future research should investigate active VR
interventions in addition to passive distraction experiences. It is unknown exactly how
VR works to reduce pain perception. VR is thought to create an immersive distraction
that restricts the mind from processing pain. The authors state that these results indicate
that VR is an effective, safe, and feasible intervention to aid with pain management.
Larger randomized clinical trials are needed to better characterize its impact on longerterm pain perception resource utilization, and post discharge outcomes.
Application of music VR for pain management. A study by Finlay (2013)
investigated the impact of music listening on chronic pain. Using questionnaire-based
approaches of pain assessment and music therapy, 23 participants (chronic pain suffers)
listened to music for 28 days. Questionnaire-based results indicated that music listening
contently reduced pain intensity. Music VR performance demonstrated that chronic pain
suffers showed pain-related cognitive interference. This suggests that music-induced
analgesia reduce pain receptors.
Koenig, Oelkers, Wormit, Bardenheurs, and Reach (2013) review a decade of
research in the development of active music therapy outpatient treatment in patients with
chronic pain. Published reviews over the past 10 years provides evidence that a specific
music therapy concept tailored to the patient might be able to reduce pain frequency and
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pain intensity in patients with chronic pain. The authors indicated that further studies
need to investigate the nature of these effects and their specialty.
Warth, Kessler, Koenig, Wormitt, and Hillecke (2014) evaluated the
psychological and physiological response of Palliative Care patients to a standardized
music therapy relaxation intervention in a randomized controlled trail. Music therapy is
frequently used in different Palliative care settings. Although music therapy is highly
accepted by healthcare professionals, evidence on the effectiveness of music therapy
interventions for terminally ill patients is rare. Recent reviews and reports, point out the
need of music therapists to provide an evidence-based rational for their clinical
treatments in this field. The study consists of 84 participants from palliative care unit in
Heidelberg. Participants were randomly picked and placed in either two sessions of music
therapy or two session of a verbal relaxation exercise, each lasting 30 minutes. The music
therapy sessions consist of live played monochord music and vocal improvisation, the
control group uses a prerecorded excerpt from the stress reduction program containing no
musical elements. Outcome measures include self-report data on subjective relaxation,
well-being, pain intensity, and quality of life, as well as continuous recording of heart
rate variability and blood volume pulse as indicators of antonymous nervous system
functioning. As result of the experiment, this study design to be appropriate to evaluate
the effectiveness of the music therapy relaxation intervention described. The research
methodology of this study set up a both ethically justifiable and feasible research design
that provides high methodological region capable of producing valid and reproducible
results.
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A study by Gutgsell et al. (2013) evaluated a method of pain management using
music therapy. Music therapy offers a nonpharmacological and safe alternative. In this
study, two hundred inpatients at university hospitals case medical Center were enrolled in
the study from 2009 to 2011. Patients were randomly assigned to one of two groups:
standard care alone or standard care with music therapy. Pre- and post-tests assessed the
level of pain using a numeric rating scale. The intervention incorporated live music for
relaxation. The results was a significantly greater decrease in pain scores was seen in the
music therapy group (difference in means [95%] -1.4 [-2.0, -0.8]; PL0.0001). The
conclusion of music therapy intervention, relaxation and live music, was effective in
lowering pain in palliative care patients.
Clinical effects of IMVR. An IMVR system typically consists of a 3dimensional (3D) computer generated environment that renders an interactive virtual
environment. IMVR allows a user to interact with a realistic, computer-generated
environment. VR experiences are primarily visual and auditory.
While there are recent technological advances in the field of VR and research
supporting the use of VR for pain management, there is needed research regarding the
use of IMVR and morphine with cancer patients in hospice care. VR (3D VR music
visual software) allows the hospice patient to manage their emotions, thoughts, and
moods. Music can be used as a source of distraction that may reduce pain and anxiety by
altering thoughts, emotions, or moods via inducing relaxation (Chlan et al., 2013). The
use of 3D music VR is likely well suited for pain management with patients in hospice
care and will be used in this study. In addition, hospice patients receiving music therapy
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must be assessed. Proper assessment consists of using measurement tools designed
specifically for measuring the effects on mood and pain.
Wiederhold, Soomro, Riva, and Wiederhold (2014) addressed an overview of
pain management therapies. Pain management can be divided into four categories:
physiotherapy (physical therapy), psychotherapy (psychological therapy),
pharmacotherapy (pharmacological therapy), and intervention therapy (use of
interventional applications to diagnosis or locate the patients source of pain or provide
relief). According to The International Association of Pain acute pain not treated properly
can become chronic. If chronic pain is not treated properly, it can worsen over time and
lead to a reduction in quality of life (The International Association of Pain, 2014 as cited
by Wiederhold, Gao et al., 2014). The author states that VR is capable of transporting an
individual into an alternate reality without physically leaving its current environment. VR
has been found to reduce performance on divided attention task and patients have less
attentional capacity to focus on incoming signals from pain receptors as they shift their
focus to interaction with VR. The author states that future implications of VR due to pain
in cancer patients need further exploration of VR treatment methods to relief pain
symptoms in these populations. Because pain is not monomorphic patients can develop
intolerance to treatments. This ushers in the use of VR where medications cannot go. VR
simulation can be programed to change in response to patient pain, dialing up the
“dosage” as more relief is needed, and dialing down the “dosage” as less is needed. The
ability to control the cyber dosage may prove useful for the future.
Quality of Life
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One of the most important goals in hospice care is to improve patient’s quality of
life. Luo (2012) addresses the advancements in pain research. The author expresses that
little improvement in pain medication has been obtained due to our limited understanding
of mechanisms mediating different pain, especially chronic pain. Improvement is quality
of health care and medicine is likely to increase the demand for better pain medications
for improving the quality of life for those living in pain. There is growing evidence
supporting VR technology emergence within the medical research for treating pain, and
growing evidence providing VR to be an effective strategy based on pain distraction.
When pain no longer dominates their lives, they can focus on the time they have left.
Kaur (2013) analyze the role of Palliative care in improving quality of life among
advanced cancer patients. Palliative care is the total care of patients whose disease is not
responsive to curative treatment. The control of pain, other distressing symptoms and
improving quality of life are important goals of Palliative Care. The author collected data
using QLQ-C30 questionnaire from 30 advanced cancer patients at their first and second
visit to a palliative care unit in a tertiary care Centre. The physical functioning among
advanced cancer patients was found to be lowest and cognitive functioning was found to
be highest at the first baseline assessment. The emotional, social and more functioning
showed improvement with palliative care. Findings of the study shows that advanced
cancer patients benefited from the palliative care. The author concluded that palliative
care plays a very crucial role in improving QOL among advanced cancer patients.
Quality of life at the end of life. Peppercorn et al. (2011) explained that when a
cure is no longer optional for patients dying of cancer, the focus of care turns from
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prolonging life to promoting the quality of life. Institute of Medicine, (IOM, 1997) issued
a report on improving care at the end of life. The report explained that to ensure better
care at the end of life, researchers need to fill gaps in knowledge about end of life.
Deng et al., (2011) evaluated the relationship between pain and quality of life
(QOL) in patients newly admitted to Wuham Hospice Center, China. A total of 1634
patients were analyzed in this retrospective study. The authors used a numerical rating
scale and Chinese-QOL instrument to assess pain score and QOL, respectively. Most
patients experienced moderate to severe pain, which significantly impaired QOL. The
authors stated that the pain was significantly correlated with appetite, mood, sleep,
fatigue, pain intensity, daily activity, side effect, general appearance, and support from
family. There was no correlation with support from society, understanding of cancer, or
attitude toward treatment. The authors concluded that the relationship between pain and
QOL was found to be reciprocal.
Meneguin, Mators, and Ferreira (2018) objective was to understand the perception
of cancer patients in palliative care in relation to quality of life and identify proposals for
improvement. A qualitative and quantitative research was carried out with 96 patients in
palliative care in a public hospital outpatient clinic, from March 2015 to February 2016.
Regarding the characteristics of the participants, 60.4% were females, Catholic (69.8%)
and companion (61.5%). For the authors to assess the quality of life in palliative care, the
authors used psychometric instruments. In this research, the relationship between health
and quality of life become evident when the participant’s referred to the pain in the final
stage of the disease. Palliative care approach aims to improve the quality of life of
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patients by relieving pain and suffering and by controlling signs and symptoms, together
with psychosocial and spiritual support. Before the challenge of taking care of end-of-life
patients, it is necessary to expand the understanding of the human being beyond the
biological dimension, to understand the suffering mentioned by participants.
Zhang, Nilsson and Prigerson (2012) determine the factors that most influence
Quality of Life (QOL) at the End-of-Life (EOL), thereby identifying promising targets
for interventions to promote QOL at the EOL. The authors state that when curative
treatments are no longer options for patients dying of cancer, the focus of care often turns
from prolonging life to promoting quality of life (QOL). Few data exist on what predicts
better QOL at the end of life (EOL) for advanced cancer patients. The authors study
consist of 396 advanced cancer patients and their caregivers who were enrolled from
September 1, 2002, through February 28, 2008. Patients were followed up from
enrollment to death a median of 4.1 months later. Patient QOL in the last week of life
was primary outcome of coping with cancer and the present report. The authors
conclusion was that advanced cancer patients who avoid hospitalization and the intense
care unit, who are less worried, who pray or meditate, who are visited by a pastor in the
hospital/clinic, and who feel a therapeutic alliance with their physicians have the highest
QOL at EOL.
Healthy People 2020 address health-related Quality of Life (HRQOL) as a multidimensional concept that includes domains related to physical, mental, emotional, and
social functioning. It goes beyond direct measures of population health, life expectancy,
and causes of death, and focuses on the impact health status has on quality of life. This
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organization addresses a related concept of HRQOL as well-being, which assess the
positive aspects of a person’s life, such as positive emotions and life satisfaction. This
organization addresses that clinicians and public health officials have used HRQOL and
well-being to measure the effects of chronic illness and treatments. While there are
existing measures of HRQOL and well-being, methodical development in this area is still
ongoing. In 1995, the WHO recognized the importance of evaluating and improving
people’s Quality of Life. The WHO 3-step “analgesic ladder”, designed to facilitate and
standardize pharmacologic cancer pain management and advises physicians worldwide
how to better provide pain management to their patients, is widely used.
Summary and Conclusions
According to Li et al. (2011), “To date, virtual reality has shown the best promise
as a complementary pain management practice” (p. 147). VR has been used to manage
pain and distress associated with chronic pain. In clinical settings and environmental
studies, participants immersed in VR experienced reduced levels of pain, distress and
unpleasantness. VR acts as a nonpharmacological form of analgesia by exerting an array
of emotional, cognitive and attentional processes on the body’s intricate pain modulation
system. In addition, mechanistic theories highlighting VR distraction conclude with new
directions in VR research, implications and clinical significance. While there is
substantial research supporting the use of VR for chronic pain management,
investigations must be conducted to further understand VR’s role in chronic pain
management with patients in hospice. Preliminary studies have demonstrated that VR
was effective in pain management. As the field advances, VR may reduce or eliminate
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the need for opioid during the last days of life. Future investigation of VR for chronic
pain management is warranted. Future studies can continue to analyze and conduct
accurate methodologies with standardized outcomes to evaluate the efficacy of VR for
chronic pain management (Li et al., 2011).
Li et al. (2011), states that present study investigations are currently underway to
determine VR as a tool for pain management with adult cancer patients in hospice care.
The results of this study will provide needed insights into the processes by which
morphine and VR together can effectively decrease pain in these patients. Insights from
this study would aid the health care team in helping cancer patients in hospice care to
cope successfully, thus enhancing the patient’s quality of life at the end of their life. The
research would also provide valuable knowledge for the use of VR and treatment of
chronic pain, which promises to facilitate positive social change in terms of improving
the quality of life for cancer patients in hospice.
Based on the review of the literature, there is currently a good understanding of
the efficacy of VR and morphine with cancer patients in hospice. The significance of the
results of their study using immersive VR as an adjuvant intervention is more effective
than morphine in relieving pain and anxiety. Furthermore, VR is a safe intervention more
pharmacological treatment. Future research suggested increasing the time of VR session
to distract them during their hospitalization stay. Future research should measure the
effectiveness of VR along with other diagnosis. Research should compare VR to other
distraction techniques such as imagination, music and art therapies. Furthermore,
researchers recommended to examine if patients have the VR equipment at home making
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it feasible to use frequently and without hindering the activities of daily living
(Mohamad, Eslam, Ahmad, and Muayyad, 2018). The current study focuses on the
following research question: “Is there a difference in pain experienced and pain perceived
for cancer patients in hospice care using only morphine and patients using IMVR and
morphine?” The research question will be addressed through the analysis of archival data.
This study’s research design is quantitative. A research design is used to structure
the research. The design will show how all the major parts of the research project,
including the sample, measures and methods of assignment work together to address the
central research questions in the study. Chapter 3 will begin with identifying the purpose
of the study, and will continue with a detailed description of the proposed research
method for the study.
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Chapter 3: Research Method
Introduction
Managing pain is critical to cancer patient’s quality of life at end of life.
According to the WHO (2014), a developing and promoting palliative care and pain relief
protocol for national health systems, strongly advocates morphine use with palliative care
settings. Despite the availability of morphine for cancer pain, the management of pain in
people with cancer remains inadequate. Developments in VR technology offers an
alternative approach that can be used to lessen the perceived pain experienced by cancer
patients engaging in hospice and improve their quality of life. The purpose of this
quantitative study was to examine an intervention that could lessen the perceived pain
experienced by, and increase the quality of life of, cancer patients engaging in hospice. In
this study I explored the possible linkage between (a) the emotional/physical pain
experiences of end of life cancer patients, and (b) pharmacological analgesics and VR.
More specifically, I investigated if there were any between-group differences in pain
perceived, pain experienced, and quality of life. I report the findings based upon the
methodology applied to gather information.
This chapter includes a presentation of the research methodology, design, and the
rationale for the choice of this method, followed by a description of the sample
population, participants, procedures and compliance with ethical guidelines. This chapter
covers data analysis plan and any threats to validity this study encountered. This chapter
concludes with a summary.
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Research Design and Rationale
Archival research data was used for this study. The variables in this study were
the independent variables (participants who received morphine medication only and
participants who received IMVR and morphine medication) and the dependent variables
(pain perceived, pain experienced, and quality of life). I used a two-group
nonexperimental design to determine the need for further information to improve pain
management for cancer patients who suffer chronic pain at the end of life.
In this study I examined the relationship between groups of participants who (a)
received morphine medication only, and (b) received IMVR and morphine medication.
The unique strength of a two-group non-experimental design is its ability to identify a
link through treatment manipulation, while controlling for the effect of extraneous
variables. This design is considered a very vigorous design (Campbell & Stanley, 1963).
There were no time and resource constraints with this choice of design as I utilized online
archival data.
Li et al. (2011) have studied various aspects of managing pain. However, new
studies can be conducted in the area of pain management, such as analyzing the impact of
IMVR on pain management practices. The current IMVR investigations were aimed to
explore an intervention that could lessen the perceived pain experienced by, cancer
patients engaging in hospice and improve their quality of life. Although IMVR
technology have been studied with cancer patients for rehabilitation (Hoffman et. al.,
2004); IMVR technology will give cancer hospice patients a quality of life at the end of
life.
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Research can help to solve the problem of cancer patients’ chronic suffering and
improve their quality of life at the end of life. A practical contribution of this study is the
advancement of human knowledge regarding VR’s role in chronic pain management with
patients in hospice (Li, Montano, Chen, & Gold 2011).
Methodology
The Population of the Study
The population from which participants were culled for this study was limited to
adult cancer patients in hospice. According to NHPCO (2013), 48% (i.e., 686,400) of
1.43 million people were hospice patients and were chronically ill. Among hospice
patients, 27.2% (186,700) were cancer patients. This population of cancer patients
included adult cancer patients in hospice using only morphine.
Sampling and Sampling Procedures
In this study, sampling was the process of selecting participants from the
population of interest. Every member of the population of interest had an equal
opportunity of being selected. In this study, the sampling frame included all individuals
in the cancer hospice population. I assembled information from the NHPCO database to
create the sampling frame. I determined the minimum sample size of 176 using the G*
Power software for a MANOVA with 2 groups and 3 dependent variables using the
following parameters: an effect size = 0.10, an alpha = .05 and a power = .95. According
to Cohen (1988) power, effect size, sample size and alpha are related, such that, each is a
function of the other three. In other words, if three of these values are fixed, the fourth is
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completely determined. For example, increasing effect size decreases subjects with a
given power and alpha level.
The effect size (.10) measured the difference between the two groups (treatment
and control group) and measured the effectiveness of the treatment. Cohen (1988) has set
out standardized measures of effect size. Cohen proposed a simple categorization of
small, moderate and large effect size. The alpha level (level of significance, p = 0.05)
rejected the null hypothesis. There is no difference in pain experienced, pain perceived,
and perceived quality of life by hospice cancer patients using (a) only morphine or (b)
IMVR and morphine to show that differences in the treatment’s outcomes are true. The
power level (.95) detected a difference of effect size specified, if such differences are
present. The power level minimized the risk of failing to detect a real effect and reject a
false null hypothesis. The minimum sample size for the current study was determined to
be 176. The sample for this study was drawn from existing data provided by NHPCO
dataset.
Procedures Using Archival Data
In this study, I utilized archival data to answer the study’s research questions.
Utilizing existing datasets was most appropriate because (a) the study’s variables was
directly pertinent to the research questions, (b) the data was readily available, (c) the data
was reliable, and (d) the database focused on information relevant to the current study.
Utilizing existing datasets is an effective way to reduce threats to internal validity like
experimenter bias (Cook & Campbell, 1979). According to Cook and Campbell (1979),
much effort has been made to avoid or reduce threats to internal validity (i.e., cause and
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effect). Datasets can support or improve the generalizability of a study’s results (Cook &
Campbell, 1979). Because generalizability of the results is a key aspect of quantitative
research, sampling strategies tend to focus on the random selection of participants. To
support the validity generalizing the results, quantitative research typically collected data
from a large number of individuals. The reason for using large samples is to collect data
broadly enough so that the data would mirror the substantially larger population from
which the sample was drawn.
Data was collected and recorded by the NHPCO. The NHPCO is a nonprofit
membership organization representing hospice and palliative care programs and
professionals in the United States. The organization reports being committed to
improving end of life care and expanding access to hospice with the goal of profoundly
enhancing quality of life for people dying in America. As defined by the WHO in 1990,
palliative care seeks address not only physical pain, but also emotional, social, and
spiritual pain to achieve the best possible quality of life for patients. The NHPCO aim is
to promote comfort and dignity for end-of-like patients (http: //www.nhpco.org).
I conducted statistical analysis using the statistical program for the social sciences
(SPSS; IBM Version 24.0, 2016) statistical package. These data sets were downloadable
and were linked to websites that accessed the data. The data were publicly available. The
data did not include identifiable information. The IRB recognizes that publicly available
data do not constitute human subjects research as defined by the 2009 U.S. Department of
Health and Human Services Code of Federal Regulations, Protection of Human Subjects
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and that their use does not require IRB review. However, the IRB approval is required
before collection of any data.
Grouping of Participants
Operational definition refers to how a specific value is defined and measured in
the study (Mclead, 2018). To operationalize the independent variables in this study,
participants were identified as members as one group or another (a) those who did not
have IMVR, and (b) those who had IMVR. Those who did not have IMVR were
operationally defined as those hospice cancer patients in the NHPCO dataset who
received morphine treatment only. The WHO has endorsed morphine as the gold standard
for opioids and has considered it to be the first line treatment for moderate to severe pain
(Ensor & Middlemiss, 2011). Additionally, morphine maybe combined with adjuvant
therapies to keep the patient as comfortable and connected to the world as possible
(Christo & Mazloomdoost, 2008). Those who had IMVR were operationally defined as
those hospice cancer patients who received IMVR in addition to the morphine treatment.
According to Chlan et al. (2013), there have been recent technological advances in the
field of VR and research supporting the use of VR for pain management. Additionally,
research regarding the use of VR and morphine with cancer patients in hospice care has
been insightful. Immersion VR (i.e., 3D VR music visual software) allows the hospice
patient to manage their emotions, thoughts, and moods. Music is used as a source of
distraction that may reduce pain and anxiety by altering thoughts, emotions, or moods via
inducing relaxation (American Pain Society, 2012).
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In this study, the NHPCO dataset contained the independent variable (morphine
only) that was changed or controlled to test the effects on the dependent variable. The
dependent variable (IMVR and morphine) was tested and measured. Regression analysis
identifies the relationship between two or more variables of interest. Regression analysis
mathematically describes the relationship between the independent variable and
dependent variable. It also allows the prediction of the mean value of the dependent
variable when the independent variable had been specified. Regression analysis allowed
prediction of the mean value of the dependent variables when the value of the
independent variable is known (Holden & Holden, 2013).
Data Analysis
Using SPSS, a MANOVA assessed whether there existed any statistically
significant between-group (i.e., those who received VR and those who did not received
VR) differences on pain perceived, pain experienced, and quality of life.
Prior to data analysis, data cleaning process ensured that the data from NPHCO
database was correct, consistent, and usable by identifying, correcting, and/or deleting
any errors that could had an impact on the results. After data was collected from the
NPHCO database, outliers were introduced to the population. Outliers would be a result
of a mistake during data collection, or it would be just an indication of variance in data.
There are two types of analysis to find the outliers- univariate (one variable outlier
analysis) and multivariate (two or more variable outlier analysis). The existence of
univariate and multivariate outliers would influence the outcome of statistical analysis.
According to Grubbs (1969) an outlier is a sample that appears to deviate markedly from
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other members of the sample in which it occurs. Univariate and multivariate outliers was
identified with the use of Mahalanobis distances among the participants. The
Mahalanobis distance, introduced by Mahalanobis in 1936, measures the distance
between a point P and a distribution D. I used Mahalanobis distance to find outliers in
NHPCO dataset. Using SPSS, MANOVA allowed the calculation of the Mahalanobis
distance and the probability associated with each score to identify outliers.
The following research questions guided this research:
RQ1: Is there a difference in pain experienced by hospice cancer patients using
(a) only morphine or (b) IMVR and morphine?
H0l: There is no difference in pain experienced by hospice cancer patients using

(a) only morphine or (b) IMVR and morphine.
HA1: There is a difference in pain experienced by hospice cancer patients using
(a) only morphine or (b) IMVR and morphine.
RQ2: Is there a difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine?
H02: There is no difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine.
HA2: There is a difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine.
RQ3: Is there a difference in perceived quality of life by hospice cancer patients
using (a) only morphine or (b) IMVR and morphine?
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H03: There is no difference in perceived quality of life by hospice cancer patients
using (a) only morphine or (b) IMVR and morphine.
HA3: There is a difference in the perceived quality of life by hospice cancer
patients using (a) only morphine or (b) IMVR and morphine.
Descriptive statistics described and summarized the population of interest in the
NHPCO data set. Descriptive statistics provided valuable information about variables in
the NHPCO dataset and highlighted potential relationship between variables. Measures of
central tendency were the most basic and, often the most informative description of a
population’s characteristics. Measures of central tendency described the central position
of a frequency distribution for a group of data using mode, median, and mean. Measures
of spread described how similar or varied the set of observed values were for a particular
variable (data item). Measures of spread included range, quartiles, absolute deviation,
variance and standard deviation.
Inferential procedure was used to test the hypotheses and generalize results to the
population as whole. The statistical tests (i.e., MANOVA) identified if there were or were
not a statistical difference in pain perceived, pain experienced, and quality of life in those
hospice cancer patients who used IMVR and those who did not used IMVR. The
alternative hypothesis states there is a relationship between group differences in pain
perceived, pain experience and quality of life.
Threats to Validity
External Validity
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External validity refers to the extent to when the results of a study can be
generalized to other settings (ecological validity), other people (population validity) and
over time (historical validity) (Mcleod, 2013). Threats to external validity have been
identified as sampling errors that can cause problems with external and internal validity.
The researcher must justify the generalizability of the sample. The study is considered
externally valid if the researcher’s conclusion can be generalized to the population at
large. Threats to external validity have been identified as using archival data. Earlier
experimental treatments or earlier measurement treatments of the dependent variable may
affect later measurements (Campbell & Stanley 1963; Cook & Campbell, 1979). The
current study applied the conclusion or results by generalizing to and across other
situations, people, stimuli, and times. External validity is how far the results of the study
can be generalized to the real world. External validity answered the question: Can my
research be applied to the real world?

Internal Validity

Internal validity refers to whether the effects observed in a study are due to the
manipulation of the independent variable and not some other factor (Mcleod, 2013). The
threats to internal validity have been identified as failure to operationalize that can lead to
the researcher drawing inappropriate conclusions about the research question. Threats to
internal validity have been identified as evaluating the reliability of measurement.
Without reliable measurement, we may falsely conclude that the independent and
dependent variable do not cavort. Threats to internal validity have been identified as
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participants in differing research groups are not randomly chosen; we may confuse
differences in the participants who make up the groups with the effect of the different
experimental treatments. Threats to internal validity have been identified as instrument
instability. Researchers affirm that an instrument that is not reliable cannot be valid;
however, a reliable instrument can sometimes, be invalid. Thus, a high reliability does
not ensure instrument validity (Polit & Beck, 2011). The current study established a
trustworthy cause-and-effect relationship between a treatment and an outcome. It also
reflected that this study made it possible to eliminate alternative explanations for my
findings.
Ethical Procedures
The participants’ records in this study do not include any personal identifiable
information. This study involved the collection of existing data. These sources were
publicly available. Since the analysis of internet archives does not constitute an
interaction with a human subject, and since it avails itself of existing records, then for
IRB purposes, it may be no different than research using old newspapers stories,
broadcasts, the congressional record, or other archival data for research (Walther, 2002).
Summary
This chapter outlined the methodological plan for this dissertation. Additionally,
Chapter 3 provided a justification for the chosen design. This chapter described the
research methodology, including the population, sample, data collection, as well as
strategies used to ensure the ethical standards, reliability and validity of the study. The
use of archival data, collected and available at National Hospice Palliative Care
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Organization, will allow the researcher to answer the study’s research questions. Lastly,
SPSS computer software was used to analyze the archival data and gathering procedures.
The following chapter 4 (Presentation of Findings) discusses in detail the results.
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Chapter 4: Results
Introduction
The purpose of this quantitative study was to explore an intervention that may
lessen the perceived pain experienced by, and increase the quality of life of, cancer
patients engaging in hospice. In this study I intended was to identify if a link exists
between morphine and IMVR with hospice cancer patients’ experiences of pain
perceptions of pain, and quality of end of life. I used a two-group nonexperimental design
to examine the relationship between groups of participants who (a) received morphine
medication only, and (b) received IMVR and morphine medication. I reviewed archival
datasets that are available to the public. These datasets compared pain scores by
hospitalized cancer patients exposed to immersive video and in-room television between
November 2016, and July, 2017 (Spiegel, Fuller, Lopez, et al., 2019). I analyzed data
using SPSS 25 software to answer the following research questions:
RQ1: Is there a difference in pain experienced by hospice cancer patients using
(a) only morphine or (b) IMVR and morphine?
H0l: There is no difference in pain experienced by hospice cancer patients using

(a) only morphine or (b) IMVR and morphine.
HA1: There is a difference in pain experienced by hospice cancer patients using
(a) only morphine or (b) IMVR and morphine.
RQ2: Is there a difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine?
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H02: There is no difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine.
HA2: There is a difference in pain perceived by hospice cancer patients using (a)
only morphine or (b) IMVR and morphine.
RQ3: Is there a difference in perceived quality of life by hospice cancer patients
using (a) only morphine or (b) IMVR and morphine?
H03: There is no difference in perceived quality of life by hospice cancer patients
using (a) only morphine or (b) IMVR and morphine.
HA3: There is a difference in the perceived quality of life by hospice cancer
patients using (a) only morphine or (b) IMVR and morphine.
I used inferential procedures to test the hypothesis and generalize results to the
population as a whole. In this chapter, I discuss and summarize data collection , describe
and summarize demographic characteristics, share the population of interest, present
quantitative analysis, and provide interpretations of the results.
Data Collection
I collected data for the study from the NHPCO. Participants included 176 (88
control group, 88 IMVR group) adult cancer patients in hospice. Raw data consisted of
patients pretest and posttest scores before and after treatment. The assessments were
completed by these patients in July 2017. Archival datasets were downloaded into
Microsoft Excel and then transferred to SPSS. Data cleaning process ensured that the data
from the database was correct, consistent, and usable by identifying, correcting and/or
deleting any errors that had an impact on the results. I used Mahalanobis distance to find

66
outliers in the dataset. Using SPSS, MANOVA allowed the calculation of the
Mahalanobis distance and the probability associated with each score to identify outliers.
Demographic Characteristics
More than half of hospice patients in the United States were females. In 2012,
83.4% of hospice patients were 65 years of age or older and more than one-third of all
hospice patients were 85 years of age or older. In 2012, more than 6% of patients were
identified as being of Hispanic or Latino origin. Whites/Caucasians accounted for
(82.8%) of hospice patients. Today, cancer diagnoses account for less than half of all
hospice admissions (37.7%; NHPCO, 2013).
Assumption Testing
I used normality tests to determine whether the sample data had been drawn from
a normally distributed population. I ran a Shapiro-Wilk test using SPSS. Shapiro-Wilk
tests calculate results from both control group and treatment group. The test rejects the
hypothesis of normality when the p-value is less than or equal to 0.05. A
p-value greater than .05 shows the data is normal. I found no significant departure from
normality.
I also used Skewness and kurtosis scores to determine normality of the
distribution. A skewness score of 0 is ideal, but scores can vary from -1 to +1 and still be
acceptable (George & Mallery, 2016). Skewness is a measure of the symmetry of the
scores, while kurtosis is a measure of shape of the distribution (Field, 2009). Kurtosis
scores from -2 to +2 are still considered acceptable (George & Mallery, 2016). Tests for
the skewness and kurtosis of control group pain scores and treatment group pain scores
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were run. The assumption of normality was met for both control group and treatment
group. The results are shown in Table 1.

Table 1
Standardized Skewness and Kurtosis Statistics of Participants
M

SD

Skewness
.216

Skewness
Error
.257

ControlGP
Pretest

3.25

1.548

ControlGP
Posttest

5.50

Kurtosis

Kurtosis
Error
.508

-1.007

1.546

-.143

.257

-.800

.508

TreatmentGP 3.47
Pretest

1.422

-064

.257

-.711

.508

TreatmentGP 5.83
Posttest
Note. N = 176

1.484

-.279

.257

-.629

.508

I assessed data for multivariate outliers using Mahalanobis distance. I ran linear
regression to assess for multivariate outliers. Multivariate outliers will be present
whenever the values of the new probability variables are less than .001. An observation
can be considered extreme if Mahalanobis distance exceeds 9.21 (Tabacnick, Fidell,
2013). The p-value in both control group and treatment group showed p-values of (.060
through .960).There were no multivariate outliers identified.
I assessed homogeneity of variances using Levene’s test of equality of variances.
To meet the assumption of homogeneity of variance, the p-value for Levene’s test should
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be above .05. If Levene’s test yields a p-value below .05, then the assumption of
variances has been validated. The significant (2-tailed) value tells if two condition means
are statistically different. If the significant (2-tailed) value is greater than .05, there is no
statistically significant difference between the two conditions. The assumption of
homogeneity of variance has been met. The results are in Table 2.

Table 2
Homogeneity of Variance
Sig(2-tailed)
ControlGP
Pretest

.852

ControlGP
Posttest

.767

TreatmentGP
Pretest

.217

TreatmentGP
Posttest

.905

Study Results
Research Question 1
RQ 1 asked if there was a difference in pain experienced by hospice cancer
patients using (a) only morphine or (b) IMVR and morphine. An analysis of variance
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(ANCOVA) evaluated whether the dependent variable (post-test) means, adjusted for
covariate (pre-test) scores, differed between the two groups. In ANCOVA approach the
whole focus was on rather one group had a higher mean than the other group after the
treatment. The adjustment for the pretest score in ANCOVA was to make sure that any
posttest differences truly resulted from the treatment and were not some left over effect of
the pretest. The intervention group who received a treatment and the control group who
did not were measured before and after the intervention. Table 3 summarized the
descriptive statistics.
Table 3
Dependent Variable: Post-test
Group

Mean

Std. Deviation

N

Control

5.56

1.544

32

Treatment

4.75

2.540

32

Total

5.16

2.125

64

In the Test of Between-Subjects Effects, the “Sig” column presents the significant
value (p-value) of the two-way interaction effect. If p is < .05 then there is a statistically
significant two-way interaction effect. Alternatively, if p is > than .05, then there is no
statistically significant two-way interaction effect. Table 4 summarizes Tests of BetweenSubjects Effects.
Table 4
Dependent Variable: Posttest
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Source

Type III Sum

df

Mean Square

F

Sig.

Of Squares
Corrected

Partial ETA
Squared

29.714

2

14.857

3.558

.035

.104

Intercept

523.242

1

523.242

125.304

.000

.673

Pre-Test

19.151

1

19.151

4.586

.036

.070

Group

2.085

1

2.085

.499

.483

.008

Error

254.724

61

4.176

Total

1986.000

64

Corrected

284.438

63

Model

Total

The pretest denotes the covariate. If p is < than .05, then the covariate
significantly adjusts the association between the predicator and outcome variable. The
covariate pre-test p-value is .036 and is less than .05. The p-value associated with
“grouping” or categorical predictor variable is .483. If the p-value is more than .05, then
there is not a statistically significant difference between the groups or levels of the
variable. If the covariate is significant and the “grouping” or predictor variable is not,
then the ANCOVA has shown evidence that it does not adjust the association.
Research Question 2
RQ 2 asked if there was a difference in pain perceived by hospice cancer patients
using (a) only morphine or (b) IMVR and morphine. An ANCOVA evaluated whether
the dependent variable (post-test) means, adjusted for covariate (pre-test) scores, differed
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between the two groups. In ANCOVA approach the whole focus was on rather one group
had a higher mean than the other group after the treatment. The adjustment for the pretest score in ANCOVA was to make sure that any post-test differences truly resulted from
the treatment and was not some left over effect of the pre-test. The intervention group
who received a treatment and the control group who did not were measured before and
after the intervention. Table 5 summarized the descriptive statistics.
Table 5
Dependent Variable: Posttest
Group

Mean

Std. Deviation

N

Control

5.48

1.455

29

Treatment

5.38

2.367

29

Total

5.43

1.948

58

In the Test of Between-Subjects Effects, the “Sig” column presents the significant
value (p-value) of the two-way interaction effect. If p is < .05 then there is a statistically
significant two-way interaction effect. Alternatively, if p is > than .05 then there is no
statistically significant two-way interaction effect. Table 6 summarized Tests of
Between-Subjects Effects.
Table 6
Dependent Variable: Posttest
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Source

Type III Sum

df

Mean Square

F

Sig.

Of Squares
Corrected

Partial ETA
Squared

20.418

2

10.209

2.868

.065

.094

Intercept

523.130

1

582.130

163.515

.000

.748

Pre-Test

20.263

1

20.263

5.692

.021

.094

Group

.595

1

.595

.167

.684

.003

Error

195.806

55

3.560

Total

1927.000

58

Corrected

216.224

57

Model

Total

The pre-test denotes the covariate. If p is < than .05, then the covariate
significantly adjusts the association between the predicator and outcome variable. The
covariate pre-test p-value is .021 and is less than .05. The p-value associated with
“grouping” or categorical predictor variable is .684. The p-value is more than .05 then
there is not a statistically significant difference between the groups or levels of the
variable. If the covariate is significant and the “grouping” or predictor variable is not,
then the ANCOVA has shown evidence that it does not adjust the association.
Research Question 3
RQ 3 asked if there was a difference in quality of life by hospice cancer patients
using (a) only morphine or (b) IMVR and morphine. An analysis of variance (ANCOVA)
evaluated whether the dependent variable (post-test) means, adjusted for covariate (pre-
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test) scores, differed between the two groups. In ANCOVA approach the whole focus
was on rather one group had a higher mean than the other group after the treatment. The
adjustment for the pre-test score in ANCOVA was to make sure that any post-test
differences truly resulted from the treatment and was not some left over effect of the pretest. The intervention group who received a treatment and the control group who did not
were measured before and after the intervention. Table 7 summarized the descriptive
statistics.
Table 7
Dependent Variable: Post-test
Group

Mean

Std. Deviation

N

Control

5.44

1.695

27

Treatment

4.78

2.309

27

Total

5.11

2.034

54

In the Test of Between-Subjects Effects, the “Sig” column presents the significant
value (p-value) of the two-way interaction effect. If p is < .05 then there is a statistically
significant two-way interaction effect. Alternatively, if p is > than .05, then there is no
statistically significant two-way interaction effect. Table 8 summarized Tests of
Between-Subjects Effects.
Table 8
Dependent Variable: Posttest
Source

Type III Sum

df

Mean Square

F

Sig.

Partial ETA
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Of Squares
Corrected

Squared

6.002

2

3.001

.717

.493

.027

Intercept

264.597

1

264.597

63.256

.000

.554

Pre-Test

.002

1

.002

.000

.983

.000

Group

5.853

1

5.853

1.399

.242

.027

Error

213.332

51

4.183

Total

1630.000

54

Corrected

219.333

53

Model

Total

The pre-test denotes the covariate. If p is < than .05, then the covariate
significantly adjusts the association between the predicator and outcome variable. The
covariate pre-test p-value is .983 and is greater than .05. The p-value associated with
“grouping” or categorical predictor variable is .242. The p-value is more than .05 then
there was not a statistically significant difference between the groups or levels of the
variable. If the covariate is not significant and the “grouping” or predictor variable is not,
then the ANCOVA has shown evidence that it does not adjust the association.
Summary
This chapter contains the result of the analysis and connects the analysis back to
research questions. Data is normally distributed and homogenous. The Normality Test
was used to determine whether the sample data had been drawn from a normally
distributed population. There was no significant departure from normality was found.
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Homogeneity of Variances was assessed using Levene’s test of equality of variances. In
order to meet the assumption of homogeneity of variance, the p value for Levene’s Test
should be above .05. The assumption of homogeneity of variance was met.
Both groups are normally distributed because of the p < .05. The homogeneity
pre-test and post test showed that data in both groups are homogeneous because the
significant value is higher than p value 0.05.
The post-test was conducted after giving the treatment in order to obtain pain
scores in each group. The research finding found that patients in the treatment group had
better performance than the controlled group. The treatment group acquired the higher
score after the treatment.
Finally, to conclude based on the findings, the result of the study had positively
answered the research questions stated in the background of the study. In chapter 5, the
present study is summarized, along with the purpose and the nature of the study. Key
findings are described, interpreted, and compared to findings in the chapter 2 literature
review. Limitations, reliability and validity of the study are discussed. Finally,
recommendations for further research are discussed.
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Chapter 5: Discussion
Introduction
The purpose of this quantitative study was to explore an intervention that may
lessen the perceived pain experienced by, and increase the quality of life of, cancer
patients engaging in hospice. This chapter includes a discussion of major findings as
related to the literature on understanding pain management. A review of empirical work
addresses the possible linkage between (a) the emotional/physical experiences of end of
life cancer patients and (b) pharmacological analgesic and IMVR. This chapter concludes
with a discussion of limits of the study, areas for future research, and a brief summary.
This chapter contains discussions and future research possibilities to help answer the
research questions. There were three research questions in this study. RQ1 was used to
determine if there was a difference in pain experienced using (a) only morphine or (b)
IMVR and morphine. RQ2 was used to determine if there a difference in pain perceived
using (a) only morphine or (b) IMVR and morphine. Research question three RQ3 was
used to determine if there was a difference in quality of life using (a) only morphine or
(b) IMVR and morphine.
Interpretation of Findings
I employed descriptive statistics using the SPSS and included groups (control of
treatment) mean score and the standard deviations. In addition, ANCOVAs were
conducted to determine if there were any statistically significant differences (.05 values
or less) between-subjects effects of the treatment group and the control group.
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The result for RQ1 indicated that those who only had morphine had lower levels
of pain experienced. Pain relief scores were lower in the VR (treatment) group compared
with the control group. Finding indicated that VR distraction were not statistically
significant. VR condition reported no significant changes in pain experienced between
pre and post treatment.
The result for RQ2 indicated that those who only had morphine had lower levels
of pain perceived. Pain relief scores were lower in the VR (treatment) group compared
with the control group. Finding indicated that VR distraction were not statistically
significant. VR condition reported no significant changes in pain perceived between preand post- treatment.
The results for RQ3 indicated that those who only had morphine had lower levels
of quality of life. QOL scores were lower in the VR (treatment) group compared with the
control group. Finding indicated that VR distraction were not statistically significant. VR
condition reported no significant changes in quality of life between pre- and posttreatment.
This study’s results supported the argument that the treatment of hospice patients
with VR was not helpful to relieve pain and increase the quality of life compared to
traditional morphine medication. The current study included questions that captured the
elements of the control group and treatment group relationships. These included
questions about managing pain perceived, pain experienced, and how pain management
could lead to a good quality of life. The findings from this study support the idea that the
best approach for managing pain in cancer hospice patients is the continued use of
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morphine sans VR. This finding is congruent with other studies that identified opiates as
an effective analgesic (Kaye, 1990).
However, the findings from this study point to a particular focus on IMVR as a
possible solution to helping cancer patients decrease the pain; and the unpleasantness
associated with painful cancer treatment. The use of IMVR (Lasich, 2012) describes VR
as a powerful pain management tool. Immersion VR (3D VR music visual software)
would allow the hospice patients to manage their emotions, thoughts and moods, thereby
relieving pain perceived and pain experienced. However, this study showed a finding that
was not statistically significant. The null hypothesis was accepted for each of the three
research questions. It could also be said that this study was underpowered. The sample
size may not have been large enough to detect a between-group difference. The results
also demonstrated that the effect size was not large enough to detect a difference. The
effect sizes for research questions 1 and 2 were small, and for research question 3 there
was a medium effect.
Interpretation of Results Guided by Theories
Guiding this study were the gate control theory and the biopsychosocial model.
Gate control theory provided the opportunity to explore how the mind-body relationship
relates to the pain experienced. Gate control theory leads to non-medication treatment for
pain. Thus, the current study’s use of a non-medication intervention (i.e., IMVR) in
addition to morphine was an effort to test one aspect of gate control theory. The gate
control pain management strategy and its application can test the concepts of the gate
control theory in pain in humans (Nathan & Rudge, 1974). Due to the prevalence of
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chronic pain conditions, this study implemented a non-medication treatment augmenting
the medication for managing pain. IMVR was used to expand on the understanding of
gate control oriented treatments and their efficacy for patients in hospice.
The biopsychosocial perspective was also a grounding theory of this study as it
provided an approach to understanding the concept of pain. The biopsychosocial
perspective viewed pain as an interaction of biological, psychological, and social factors
unique to each individual. In this study, biopsychosocial perspective considered the
hospice patient with cancer, experiences with cancer, and the cancer patient’s attitudes
toward their illness. Integrating IMVR as a treatment for patients in hospice expanded on
the understanding of biopsychosocial oriented treatments and their efficacy for patients in
hospice.
Limitations of the Study
There were some limitations in this study. The first limitation was the small
number of participants. This study’s findings were based on the sample size and effect
size calculated for the analysis. The sample size for this study was 176. Cohen’s d effect
size used to indicate the standardized difference between two means were small and
medium effect size.
The second limitation was the current study’s results were only applicable to a
very narrow population of hospice patients, with a specific illness (cancer), gender, age
and setting of the sample group.
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Recommendations
One recommendation would be to conduct this study with a larger and more
diverse population. In this study, more than half of hospice patients in the United States
were females, and 83.4% were White. As the current study did not identify a between
group statically significant difference, further investigations, and with larger samples and
refined methodologies are higher recommended.
Another recommendation would be to use data sets that contain psychosocial
variables. Variables such as anxiety, hopelessness, and depression could provide more
insights. To understand social behavior, the concepts of interest must be measured. This
study’s interest was in how cancer hospice patients feel their thoughts, emotions, and
behaviors. One approach to measurement involves directly asking patients about their
perceptions using self-report measures. Behavioral measures are measures designed to
directly assess what people do. Social neuroscience measures social responses in the
brain. In this study, I used an archival dataset. Participants’ self-reports of their feelings
and thoughts, and observations of participants’ behaviors were not included in the current
study. Evaluating these constructs first-hand rather than via second-hand data sets could
improve the study’s validity. Gatchel et al. (2007) emphasized the significant role that
psychosocial factors potentially play in people’s perception of pain. Physical symptoms
like pain can be affected by psychosocial factors via awareness, how patients think about
pain, emotional responses to pain and how patients’ coping skills affect the level of pain.
Assessing the impact of psychosocial factors on pain could provide results with higher
levels of validity.
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A final recommendation would be to provide end users (i.e., hospice patients)
with explicitly and scientifically validated training on the optical use of VR. In this study
VR participants have not received training and thus may not have used the IMVR
effectively.
Implications
The data from this study reveals practical applications worthy of future study.
This study tested the effectiveness of a non-pharmacological (IMVR) treatment along
with morphine to relieve pain and increase quality of life. This study’s results indicated
that IMVR along with morphine was not effective in relieving pain in hospice patients
with cancer. Yet, the ability to transport the patient into a virtual world for the purpose of
distraction makes IMVR a powerful tool. Knowledge and understanding of IMVR tool
can transform the way we treat and control pain. Findings may also shed light on IMVR
as an invention for healing emotional pain of patients by reducing anxiety and feelings of
isolation.
Conclusions
This current research was conducted using a sample of participants who were
cancer hospice patients, were at the end of life, and were being treated with morphine and
IMVR for pain management; archival data were used for this study. The data was
analyzed using descriptive statistics and an ANCOVA was used to test main and
interactions effects to answer the research hypotheses. The results for each hypothesis
were not statistically significant. To understand the strength of the difference between
two groups (control vs treatment), an effect size was calculated. A small effect size

82
determined that two variables had small effect and only one variable had medium effect.
The larger the effect size the stronger the relationship between two variables.
Recommendations include: increasing the number of study participants, adding more
psychosocial variables to surveys used to access data, more diversity of participants, and
future studies using IMVR. The results of this study add to the growing body of literature
that supports the importance of improving pain management in the hospice population.
This study design presented a broader spectrum of information allowing not only for a
clearer path of treatment, but also for implementing a better treatment plan.
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